Version 1
: Received: 11 May 2024 / Approved: 13 May 2024 / Online: 13 May 2024 (12:14:22 CEST)
How to cite:
Chewaskulyong, B.; Satjaritanun, P.; Tantraworasin, A.; Ketpueak, T.; Suksombooncharoen, T.; Charoentum, C.; Nuchpong, N. Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer Patients. Preprints2024, 2024050843. https://doi.org/10.20944/preprints202405.0843.v1
Chewaskulyong, B.; Satjaritanun, P.; Tantraworasin, A.; Ketpueak, T.; Suksombooncharoen, T.; Charoentum, C.; Nuchpong, N. Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer Patients. Preprints 2024, 2024050843. https://doi.org/10.20944/preprints202405.0843.v1
Chewaskulyong, B.; Satjaritanun, P.; Tantraworasin, A.; Ketpueak, T.; Suksombooncharoen, T.; Charoentum, C.; Nuchpong, N. Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer Patients. Preprints2024, 2024050843. https://doi.org/10.20944/preprints202405.0843.v1
APA Style
Chewaskulyong, B., Satjaritanun, P., Tantraworasin, A., Ketpueak, T., Suksombooncharoen, T., Charoentum, C., & Nuchpong, N. (2024). Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer Patients. Preprints. https://doi.org/10.20944/preprints202405.0843.v1
Chicago/Turabian Style
Chewaskulyong, B., Chaiyut Charoentum and Nuttaphoom Nuchpong. 2024 "Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer Patients" Preprints. https://doi.org/10.20944/preprints202405.0843.v1
Abstract
Cancer patients, susceptible to severe COVID-19 outcomes, exhibit varied vaccine responses, particularly those who are receiving chemotherapy. This prospective cohort study enrolled 115 cancer patients, and data from 91 patients who received two doses of COVID-19 vaccines were analyzed. Blood was drawn at baseline, day 28, and 6 months post-second dose for neutralizing antibody analysis. The primary outcome was seroconversion rate against wild type and Omicron at day 28. Secondary outcomes included seroconversion at 6 months, factors associated with seroconversion, and safety. Of the 157 cancer patients screened, 91 were enrolled, with 45% receiving chemotherapy. Seroconversion rates at day 28 were 77% for the wild type and 62% for Omicron. Chemotherapy did not affect seroconversion (p=0.789 for wild type, p=0.597 for Omicron). Vaccine type positively correlated with seroconversion, with an adjusted ORR of 25.86 (p=0.029) for the wild type and 17.38 (p<0.001) for Omicron with the primary heterologous vaccine. Adverse events were grade 1 in 34.0% and grade 2 in 19.7% of participants. Despite lower seroconversion against Omicron, no difference was noted between chemotherapy and non-chemotherapy groups. COVID-19 vaccinations demonstrated good tolerability. This data underscores vaccine efficacy considerations in cancer patients, informing tailored strategies for this vulnerable population.
Keywords
COVID-19; COVID-19 vaccines; seroconversion rate of neutralizing antibody; Solid cancer patients
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
